Quoin Pharmaceuticals Ltd. (QNRX) - 10-K Summary
Business Context and Reporting Period
Company: Quoin Pharmaceuticals Ltd.
Reporting Period: Fiscal year ended December 31, 2024
Business Model: Late-stage clinical specialty pharmaceutical company focused on rare and orphan diseases. The company has no commercialized products and has generated no revenue to date.
Lead Asset: QRX003, a topical lotion in late-stage clinical development for Netherton Syndrome (NS). The company is conducting multiple clinical studies in the U.S. and expanding internationally (Middle East, UK, Europe, New Zealand).
Other Pipeline: QRX004 (Recessive Dystrophic Epidermolysis Bullosa), QRX007/QRX008 (via QUT research agreements), and novel topical rapamycin formulations (via University College Cork agreement).
Key Financial Metrics (Year Ended Dec 31, 2024)
| Metric | 2024 | 2023 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(8,962,472) | $(8,686,573) |
| Total Operating Expenses | $9,528,465 | $9,378,504 |
| Research & Development (R&D) | $3,602,632 | $3,307,987 |
| General & Administrative (G&A) | $5,925,833 | $6,070,517 |
| Cash & Cash Equivalents | $3,623,343 | $2,401,198 |
| Investments (Marketable Securities) | $10,433,535 | $8,293,663 |
| Total Liquidity (Cash + Investments) | $14,056,878 | $10,694,861 |
| Accumulated Deficit | $(55,165,792) | $(46,203,320) |
| Net Cash Used in Operating Activities | $(7,857,309) | $(7,864,429) |
| Net Cash Provided by Financing Activities | $10,967,736 | $5,216,683 |
Material Changes vs. Prior Period
- Financing Activity: The company raised significant capital in 2024 through two public offerings (March and December), generating approximately $11.6 million in net proceeds. This contrasts with $5.8 million in net proceeds from a single offering in 2023.
- Expense Trends: Total operating expenses increased slightly by $150,000 (1.6%). R&D expenses rose by $295,000 (8.9%) due to increased clinical study expenditures and manufacturing costs. G&A expenses decreased by $145,000 (2.4%) primarily due to reduced travel and insurance costs, offset by higher payroll and legal fees.
- Liquidity Position: Total cash and investments increased by approximately $3.4 million, driven by the successful equity financings.
- Share Count: Significant dilution occurred due to the 2024 offerings. Outstanding ADSs increased from 987,220 at year-end 2023 to 8,948,164 at year-end 2024.
Guidance, Outlook, Risks, and Unusual Items
- Outlook: Management believes current cash and investments are sufficient to fund operations for at least the next 12 months. However, additional financing will be required to complete clinical development and commercialization.
- Clinical Progress: Positive interim data was reported for QRX003 in both adult and pediatric studies. A new study applying the drug to >80% of body surface area was cleared by the FDA in December 2024.
- Nasdaq Listing Risk: The company received a deficiency letter in April 2024 for failing to maintain the $1.00 minimum bid price. It was granted an extension until April 28, 2025, to regain compliance. Failure to comply may result in delisting.
- Key Risks:
- Capital Requirements: History of losses and need for additional capital; inability to raise funds on acceptable terms.
- Development Risk: Clinical trials may fail to demonstrate safety/efficacy; regulatory approval is not guaranteed.
- Third-Party Reliance: Dependence on CROs and contract manufacturers for clinical trials and supply.
- Intellectual Property: Reliance on in-licensed technology (Skinvisible) and potential patent challenges.
- Unusual Items: The company incurred approximately $1.7 million in non-cash offering expenses related to the modification of existing warrants in connection with the 2024 offerings.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $14.1 million liquidity position against the estimated $3.6 million remaining cost for current clinical studies and future operational needs.
- Nasdaq Compliance: Monitor the stock price to ensure it meets the $1.00 minimum bid price requirement by April 28, 2025, to avoid delisting.
- Dilution Impact: Assess the impact of the significant increase in outstanding shares (from ~1M to ~9M) and the large number of outstanding warrants (over 50M) on future equity value.
- Clinical Data: Review the full data readouts from the ongoing QRX003 studies, particularly the new whole-body application study, to validate the efficacy claims made in the filing.
- Related Party Transactions: Note the significant indebtedness to officers (Dr. Myers and Ms. Carter) totaling approximately $2.9 million as of year-end 2024.